Alfredo Addeo Highlights Key EGFR Takeaways from RomeLung25
Alfredo Addeo, Head of the Oncology Department at Geneva University Hospitals, shared on X:
“Incredibly grateful to Federico Cappuzzo, Lorenza Landi, Tina Cascone for the invitation to speak at RomeLung25 on oncogene addicted metastatic NSCLC:EGFR. Take home messages: combo treatment better than Osi, Tox requires education and active management
Amazing to be in a session with great experts.“
This post by Alfredo Addeo reflects on his recent participation at RomeLung25, where he spoke on EGFR-mutant metastatic non-small cell lung cancer (NSCLC). His key message was clear: combination therapies outperform osimertinib monotherapy, though they bring increased toxicity. Addeo emphasized the importance of toxicity education and proactive management, especially as more complex regimens become standard. He also acknowledged the collaboration and insights from leading thoracic oncology experts, including Federico Cappuzzo, Lorenza Landi, and Tina Cascone.
To learn more read this impactful article about NSCLC on OncoDaily: Non-Small Cell Lung Cancer: Causes, Symptoms, Diagnosis, Treatment Options
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023